Replies to post #17367 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

This statement by an FDA official about interchangeable FoBs is more pertinent to MNTA’s business model (which no longer includes development of small-molecule generics):

Bullish4 $MNTA: https://t.co/vt76KBi3G6

— Roy Friedman (@DewDiligence) June 20, 2017